198 related articles for article (PubMed ID: 10731046)
1. Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats.
Loichot C; Cazaubon C; De Jong W; Helwig JJ; Nisato D; Imbs JL; Barthelmebs M
Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):319-26. PubMed ID: 10731046
[TBL] [Abstract][Full Text] [Related]
2. Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney.
Barthelmebs M; Krieger JP; Grima M; Nisato D; Imbs JL
Eur J Pharmacol; 1996 Oct; 314(3):325-32. PubMed ID: 8957254
[TBL] [Abstract][Full Text] [Related]
3. Coronary vasoconstriction produced by vasopressin in anesthetized goats. Role of vasopressin V1 and V2 receptors and nitric oxide.
Fernández N; García JL; García-Villalón AL; Monge L; Gómez B; Diéguez G
Eur J Pharmacol; 1998 Jan; 342(2-3):225-33. PubMed ID: 9548390
[TBL] [Abstract][Full Text] [Related]
4. High concentrations of oxytocin cause vasoconstriction by activating vasopressin V1A receptors in the isolated perfused rat kidney.
Loichot C; Krieger JP; De Jong W; Nisato D; Imbs JL; Barthelmebs M
Naunyn Schmiedebergs Arch Pharmacol; 2001 Apr; 363(4):369-75. PubMed ID: 11330329
[TBL] [Abstract][Full Text] [Related]
5. Enhanced renal vasoconstriction induced by vasopressin in SHR is mediated by V1 receptors.
Feng JJ; Arendshorst WJ
Am J Physiol; 1996 Aug; 271(2 Pt 2):F304-13. PubMed ID: 8770161
[TBL] [Abstract][Full Text] [Related]
6. Endothelium-dependent relaxation of human saphenous veins in response to vasopressin and desmopressin.
Aldasoro M; Medina P; Vila JM; Otero E; Martinez-León JB; Lluch S
J Vasc Surg; 1997 Apr; 25(4):696-703. PubMed ID: 9129626
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed.
Heinemann A; Horina G; Stauber RE; Pertl C; Holzer P; Peskar BA
Br J Pharmacol; 1998 Nov; 125(6):1120-7. PubMed ID: 9863637
[TBL] [Abstract][Full Text] [Related]
8. Vasopressin does not effect hypertension caused by long-term nitric oxide inhibition.
Loichot C; Cazaubon C; Grima M; De Jong W; Nisato D; Imbs JL; Barthelmebs M
Hypertension; 2000 Feb; 35(2):602-8. PubMed ID: 10679504
[TBL] [Abstract][Full Text] [Related]
9. Shear stress modulates vasopressin-induced renal vasoconstriction in rats.
Loichot C; Krieger JP; De Jong W; Helwig JJ; Nisato D; Imbs JL; Barthelmebs M
Naunyn Schmiedebergs Arch Pharmacol; 2002 Dec; 366(6):555-61. PubMed ID: 12444497
[TBL] [Abstract][Full Text] [Related]
10. V2-receptor-mediated relaxation of human renal arteries in response to desmopressin.
Medina P; Segarra G; Vila JM; Chuan P; Domenech C; Lluch S
Am J Hypertens; 1999 Feb; 12(2 Pt 1):188-93. PubMed ID: 10090347
[TBL] [Abstract][Full Text] [Related]
11. Relaxation of human isolated mesenteric arteries by vasopressin and desmopressin.
Martínez MC; Vila JM; Aldasoro M; Medina P; Flor B; Lluch S
Br J Pharmacol; 1994 Oct; 113(2):419-24. PubMed ID: 7834191
[TBL] [Abstract][Full Text] [Related]
12. Receptor subtype for vasopressin-induced release of nitric oxide from rat kidney.
Hirata Y; Hayakawa H; Kakoki M; Tojo A; Suzuki E; Nagata D; Kimura K; Goto A; Kikuchi K; Nagano T; Hirobe M; Omata M
Hypertension; 1997 Jan; 29(1 Pt 1):58-64. PubMed ID: 9039081
[TBL] [Abstract][Full Text] [Related]
13. Cerebral vasoconstriction produced by vasopressin in conscious goats: role of vasopressin V(1) and V(2) receptors and nitric oxide.
Fernández N; Martínez MA; García-Villalón AL; Monge L; Diéguez G
Br J Pharmacol; 2001 Apr; 132(8):1837-44. PubMed ID: 11309256
[TBL] [Abstract][Full Text] [Related]
14. Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans.
Weber R; Pechère-Bertschi A; Hayoz D; Gerc V; Brouard R; Lahmy JP; Brunner HR; Burnier M
Hypertension; 1997 Nov; 30(5):1121-7. PubMed ID: 9369265
[TBL] [Abstract][Full Text] [Related]
15. Regional differences in the arterial response to vasopressin: role of endothelial nitric oxide.
García-Villalón AL; Garcia JL; Fernández N; Monge L; Gómez B; Diéguez G
Br J Pharmacol; 1996 Aug; 118(7):1848-54. PubMed ID: 8842453
[TBL] [Abstract][Full Text] [Related]
16. Vasopressin-induced facilitation of adrenergic responses in the rat mesenteric artery is V1-receptor dependent.
Streefkerk JO; Pfaffendorf M; van Zwieten PA
Auton Autacoid Pharmacol; 2003 Feb; 23(1):35-41. PubMed ID: 14565536
[TBL] [Abstract][Full Text] [Related]
17. Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity.
Méchaly I; Laurent F; Portet K; Serrano J; Cros G
Eur J Pharmacol; 1999 Nov; 383(3):287-90. PubMed ID: 10594321
[TBL] [Abstract][Full Text] [Related]
18. V1a- and V2-type vasopressin receptors mediate vasopressin-induced Ca2+ responses in isolated rat supraoptic neurones.
Gouzénes L; Sabatier N; Richard P; Moos FC; Dayanithi G
J Physiol; 1999 Jun; 517 ( Pt 3)(Pt 3):771-9. PubMed ID: 10358117
[TBL] [Abstract][Full Text] [Related]
19. Interactions of adenosine A1 receptor-mediated renal vasoconstriction with endogenous nitric oxide and ANG II.
Barrett RJ; Droppleman DA
Am J Physiol; 1993 Nov; 265(5 Pt 2):F651-9. PubMed ID: 8238545
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
